Zimbabwe has declined a major US health deal worth 367 million US dollars (£272m) over five years because of Washington's demand for confidential information.
This rejection became public after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative later stated that the US was demanding access to biological samples for scientific study and profit while was unwilling to guarantee the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged further negotiations to reach a deal suitable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Implications
This rejection comes after a comparable situation in Kenya, where a court suspended a similar health funding agreement after concerns were filed about the safety of citizens' medical information.
After resuming office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance openness and accountability.
According to reports, 16 African countries have so far signed these new health pacts, representing over $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, with no equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our country would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our citizens should a new health crisis arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining structures already established via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This framework is intended to guarantee that when a country provides its samples, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing dialogue with our US partners on how future collaboration might be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body stated it understood the government's concerns, but urged that negotiations must proceed considering much of the nation's Aids initiatives depended on international support.
"If specific concerns exist, such as those involving information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
This impasse emphasises the ongoing debate between receiving crucial foreign assistance and protecting local interests in an ever more interconnected world.